Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes

NCT01107717 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT01107717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01107717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2009
Completion date
February 3, 2023
Enrollment
318 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes